MRK-Samsung/BIIB*—Phase-3 trials for Enbrel and Remicade FoBs met primary endpoint: http://finance.yahoo.com/news/merck-samsung-bioepis-announce-pivotal-124600445.html The five FoBs in this collaboration are: • Enbrel [worldwide except US/EU/Japan] • Remicade [worldwide except EU/Russia/Turkey] • Humira [worldwide except EU/Russia/Turkey] • Herceptin [worldwide] • Lantus [worldwide] Samsung Bioepis is conducting the trials in all of the above programs except Lantus, where MRK has the lead role. *d/b/a Samsung Bioepis.